VIP and L-arginine both contribute to vasodilation and NO-mediated signaling, but through distinct molecular mechanisms. VIP activates adenylate cyclase via VPAC receptors, producing cAMP-dependent vasodilation and eNOS upregulation. L-arginine is the direct substrate for nitric oxide synthase (NOS), providing the raw material for NO production. Their comparison illustrates the distinction between receptor-mediated vasodilation and substrate-dependent NO synthesis.
- Sequence: His-Ser-Asp-Ala-Val-Phe-Thr-Asp-Asn-Tyr-Thr-Arg-Leu-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Ala-Asn-Ser-Ile-Leu-Asn-NH₂ (28 amino acids)
- Origin: Enteric neurons, CNS, lungs
- MW: 3,326 Da
- Charge at pH 7.4: +2 (net)
- Receptors: VPAC1 (Gαs), VPAC2 (Gαs), PAC1 (Gαs)
- Half-life: 1–2 minutes (serum)
- Bioavailability: <1% oral; ~100% IV/inhalation
- FDA-approved indications: None (research/investigational)
- Chemical name: 2-amino-5-(guanidino)pentanoic acid
- Structure: Semi-essential amino acid
- MW: 174 Da
- Charge at pH 7.4: +1 (guanidinium)
- Receptor: NOS enzyme substrate (not receptor-mediated)
- Half-life: 1–2 hours (serum)
- Bioavailability: ~70% oral
- FDA status: Dietary supplement (not drug)
- VPAC1/VPAC2 binding: VIP activates Gαs-coupled receptors
- cAMP elevation: ↑Adenylate cyclase activity
- PKA activation: cAMP-dependent protein kinase A
- eNOS phosphorylation: Ser1177 phosphorylation (activating)
- Ca²⁺ mobilization: IP₃-mediated ER Ca²⁺ release
- NO production: eNOS converts L-arginine → NO + L-citrulline
- Vasodilation: NO → sGC → cGMP → smooth muscle relaxation
Additional effects of VPAC activation:
- ↑HCO₃⁻ secretion (intestinal)
- ↑Insulin release (pancreatic)
- ↑Prolactin release (anterior pituitary)
- ↑Growth hormone release (anterior pituitary)
- NOS binding: L-arginine binds NOS active site
- Oxidation: NOS catalyzes 2-electron oxidation
- NO generation: L-arginine → NO + L-citrulline
- Cofactor dependence: BH₄, FAD, FMN, heme, CaM
- NOS isoforms: eNOS (endothelial), nNOS (neuronal), iNOS (inducible)
NOS isoform comparison:
| Isoform | Location | Function | Regulation |
|---|
| eNOS | Endothelium | Vascular tone | Ca²⁺/CaM, phosphorylation |
| nNOS | Neurons | Neurotransmission | Ca²⁺/CaM |
| iNOS | Macrophages, many cells | Innate immunity | Transcriptional (cytokines) |
| Pathway | VIP | L-Arginine |
|---|
| Primary mechanism | VPAC → cAMP → eNOS | NOS substrate → NO |
| NO production | Indirect (eNOS upregulation) | Direct (NOS substrate) |
| Additional vasodilation | cAMP-dependent (independent of NO) | None |
| Receptor-dependent | Yes (VPAC1/2) | No (enzyme substrate) |
| Cofactor requirement | BH₄ (indirectly) | BH₄, NADPH, FAD, FMN |
| Duration | 1–2 minutes (serum) | 1–2 hours (serum) |
| Oral bioavailability | <1% | ~70% |
| Feature | VIP | L-Arginine |
|---|
| Endothelium required | Yes (for eNOS) | Yes (for NOS) |
| Smooth muscle effect | Direct (cAMP) | Indirect (NO/cGMP) |
| Endothelium-independent vasodilation | Partial (cAMP pathway) | None |
| Resistance to endothelial dysfunction | Partial (cAMP bypass) | Limited (↓eNOS function) |
| Parameter | VIP | L-Arginine |
|---|
| Half-life | 1–2 minutes | 1–2 hours |
| Oral bioavailability | <1% | ~70% |
| IV half-life | 1–2 minutes | 1–2 hours |
| Inhalation | Effective (lung) | Limited |
| Distribution | Brain, gut, lungs | Systemic |
| Metabolism | Rapid peptidase degradation | Hepatic (arginase) |
| Excretion | Hepatic/renal | Renal |
| Indication | Route | Dose | Evidence |
|---|
| Pulmonary hypertension | Inhalation | 50 µg TID | Moderate |
| Vasoactive intestinal tumor | IV | Variable | Limited |
| Erectile dysfunction | Injection (intracavernosal) | 20 µg | Moderate |
| Asthma (adjunctive) | Inhalation | Variable | Emerging |
| Sepsis-associated vasodilation | IV | Variable | Investigational |
| Indication | Route | Dose | Evidence |
|---|
| Endothelial dysfunction | Oral | 3–6 g/day | Moderate |
| Intermittent claudication | Oral | 6–10 g/day | Moderate |
| Erectile dysfunction | Oral | 1.5–5 g/day | Weak–Moderate |
| Hypertension (adjunctive) | Oral | 6–10 g/day | Weak–Moderate |
| Heart failure | Oral | 5–10 g/day | Moderate |
| Wound healing | Oral/IV | Variable | Emerging |
| Adverse Effect | Frequency | Severity | Mechanism |
|---|
| Facial flushing | 20–30% | Mild | Vasodilation |
| Hypotension | 10–20% | Moderate | Vasodilation |
| Headache | 10–15% | Mild | Cerebral vasodilation |
| Diarrhea | 5–10% | Mild | Intestinal secretion |
| Bronchospasm | Rare | Moderate | Airway reactivity |
| Adverse Effect | Frequency | Severity | Mechanism |
|---|
| GI distress | 10–20% | Mild | Osmotic effect |
| Diarrhea | 10–15% | Mild | Osmotic |
| Nausea | 5–10% | Mild | GI irritation |
| Bloating | 5–10% | Mild | GI fermentation |
| Hypotension | Rare | Moderate | Excessive NO |
| Worsening asthma | Rare | Moderate | Airway NO |
| Herpes reactivation | Rare | Moderate | ↑Arginase competition |
| Interacting Agent | Effect | Severity |
|---|
| Nitrates | Additive hypotension | Moderate |
| PDE5 inhibitors | Additive vasodilation | Moderate |
| Antihypertensives | Additive BP lowering | Moderate |
| Insulin | ↑Insulin release | Minor |
| Interacting Agent | Effect | Severity |
|---|
| Antihypertensives | Additive BP lowering | Moderate |
| Nitrates | Additive vasodilation | Moderate |
| PDE5 inhibitors | Additive vasodilation | Moderate |
| Warfarin | ↑INR (case reports) | Moderate |
| Sildenafil | Additive hypotension | Moderate |
VIP and L-arginine both enhance NO-mediated vasodilation through fundamentally different mechanisms. VIP activates VPAC receptors, increasing cAMP and upregulating eNOS, providing receptor-dependent vasodilation with additional cAMP-mediated effects. L-arginine serves as the direct NOS substrate, providing the raw material for NO synthesis. VIP offers rapid onset but very short duration (minutes); L-arginine offers oral bioavailability and longer duration (hours). VIP may be advantageous when endothelium-dependent NO production is impaired (partial cAMP bypass), while L-arginine efficacy depends on functional NOS. Their combination could theoretically enhance NO production through both substrate supply and enzyme upregulation.
